Clinical trials
Hemophilia A clinical trials
Below are recruiting hemophilia a clinical trials, each written for real people, not researchers. We’re tracking 92 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04563520RecruitingPhase 3
Testing the safety of aPCC after emicizumab in hemophilia A
This study looks at whether aPCC (a clotting medicine) is safe to use for bleeding safety in people with hemophilia A who are already taking emicizumab. It mainly checks side effects and safety after switching to or using aPCC when needed.
Atlanta, GeorgiaAges 6 years+ - NCT05500807RecruitingPhase 1
Emicizumab study for severe von Willebrand disease or overlap disorder
This Phase 1 trial studies how well and safely emicizumab works for people with severe von Willebrand disease (VWD) or VWD plus hemophilia A. Emicizumab is a preventive medicine given regularly to reduce bleeding risk.
Orange, CaliforniaAges birth–90 years - NCT05629130Recruiting
Blocking blood vessel procedures for bleeding-related joint inflammation
This study looks at whether a “blocking” procedure (embolization) can improve long-lasting joint inflammation caused by inherited bleeding disorders. It focuses on people with joint lining inflammation from repeated bleeding into the joint.
São PauloAges Any age - NCT05895032Recruiting
Exercise program for children with hemophilia A or B
This trial studies whether a structured exercise program helps children with hemophilia A or B safely. It looks at children’s ability to exercise and function, while aiming to avoid complications like leg bleeds or injuries.
Canterbury, KentAges 6–12 - NCT05935358RecruitingPhase 4
Nuwiq added around surgery for people with hemophilia A
This Phase 4 study looks at how well Nuwiq works to manage bleeding risk around the time of major elective surgery in people with severe hemophilia A who already take emicizumab to prevent bleeds. It may help your surgical team plan safer blood-clotting support during and after surgery.
Dallas, TexasAges 12 years+ - NCT05936580RecruitingPhase 4
Nuwiq dosing for girls and women with hemophilia A surgery
This trial studies how to dose Nuwiq (a factor medicine) and track outcomes in girls and women with hemophilia A who need major surgery. It may help confirm the best way to manage bleeding risk around surgery.
San Antonio, TexasAges 12 years+ - NCT06142552RecruitingPhase 3
Study of a longer-lasting hemophilia A treatment for men
This trial tests a new form of factor VIII that lasts longer in the body, so you may need fewer infusions. It is for men with severe hemophilia A who have already used factor VIII products for at least 150 days.
BeijingAges 12–65 - NCT07684898RecruitingPhase 3
Long-acting factor VIII for severe hemophilia A
This trial tests a new long-acting factor VIII treatment (FRSW107) for people with severe hemophilia A. It aims to prevent bleeding episodes with fewer injections, and you must have already used factor VIII treatments many times before.
Tianjin, Tianjin MunicipalityAges 12–65 - NCT06816056Recruiting
Foot therapy for hemophilia ankle arthritis
This study tests if manual therapy can help patients with hemophilia who have arthritis in their ankle. It seeks to improve joint health and reduce pain.
MurciaAges 18–65 - NCT06941870RecruitingPhase 4
Efanesoctocog Alfa Preventative Treatment for Hemophilia A with Joint Thickening
This study tests a new preventive treatment (efanesoctocog alfa) for people with hemophilia A who have joint lining thickening. The goal is to see if it helps protect joints.
Los Angeles, CaliforniaAges 12 years+ - NCT07096349Recruiting
Chronic pain study in severe hemophilia A
This study looks at chronic pain in people with severe hemophilia A. It aims to understand pain better through questionnaires and joint health checks.
Oviedo, Principality of AsturiasAges 18 years+ - NCT07205523Recruiting
High-altitude blood study for stem cell transplant patients
This study observes how blood and stem cell transplants work for patients with blood diseases at high altitude. It aims to learn more to help future patients.
Xining, QinghaiAges Any age - NCT02453542Recruiting
Testing how blood-clotting is managed in hemophilia with inhibitors
This study looks at different ways to help blood clot in people with hemophilia who have developed inhibitors (proteins that stop standard clotting treatments from working). It may help doctors choose the safest, most effective clotting approach for these situations.
Solna, Stockholm CountyAges 7 years+ - NCT03217032RecruitingPhase 1
Gene therapy trial for hemophilia A using FVIII
This Phase 1 study tests a gene therapy designed to help the body make factor VIII (FVIII), which is missing in hemophilia A. It may help reduce bleeding and the need for FVIII infusions, but it is an early-safety trial.
Shenzhen, GuangdongAges 2–65 - NCT06940830RecruitingPhase 4
Long-term joint health study with efanesoctocog alfa
This study checks how well efanesoctocog alfa (a preventive factor VIII treatment) protects your joints over time in people with hemophilia A. It involves regular checkups, joint assessments, and tracking of any bleeding episodes.
ZagrebAges Any age - NCT07437404RecruitingPhase 3
Testing SCT800 for previously untreated severe hemophilia A
This study tests a new medicine called SCT800 for boys with severe hemophilia A who have never been treated with factor VIII before. The goal is to see if it works safely to prevent bleeding.
Beijing, Beijing MunicipalityAges Up to 6 years - NCT07545395RecruitingPhase 3
Safety study of KN057 blood clot prevention in hemophilia
This study tests whether KN057, a new preventive medicine, is safe for males with hemophilia A or B. It aims to help prevent bleeding episodes without causing unwanted blood clots.
Tianjin, Tianjin MunicipalityAges 12–65 - NCT07663903RecruitingPhase 3
New longer-lasting factor VIII for severe hemophilia A (on-demand use)
This trial tests a new longer-lasting factor VIII medicine (FRSW107) for on-demand treatment of bleeding episodes. It is for males with severe hemophilia A who have been previously treated at least 150 times.
Tianjin, Tianjin MunicipalityAges 12–65 - NCT06938542Enrolling by invitation
Palliative care needs for kids with rare diseases
This study asks children with rare diseases and their families about what kind of palliative care (comfort and support) they need. It aims to understand how to better help families through their child's illness.
Washington D.C., District of ColumbiaAges 1–99 - NCT06826209Enrolling by invitation
Comparing arm function in children with and without hemophilia
This study compares how well children with hemophilia use their arms and hands compared to healthy children. If your child has hemophilia A or B, is on regular treatment, and has no inhibitors or recent bleeds in the arm, they may be able to join.
Ankara, AnkaraAges 7–17
Hear when a new Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hemophilia a?
- Yes. Clin2 currently lists 92 recruiting hemophilia a studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hemophilia a trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hemophilia a trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.